- Home
- HCKT vs NUVB Comparison
HCKT vs NUVB Comparison
Compare HCKT & NUVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HCKT
- NUVB
- Stock Information
- Founded
- HCKT 1991
- NUVB 2018
- Country
- HCKT United States
- NUVB United States
- Employees
- HCKT N/A
- NUVB N/A
- Industry
- HCKT Professional Services
- NUVB Biotechnology: Pharmaceutical Preparations
- Sector
- HCKT Consumer Discretionary
- NUVB Health Care
- Exchange
- HCKT Nasdaq
- NUVB Nasdaq
- Market Cap
- HCKT 789.8M
- NUVB 679.9M
- IPO Year
- HCKT 1998
- NUVB N/A
- Fundamental
- Price
- HCKT $29.17
- NUVB $1.81
- Analyst Decision
- HCKT Strong Buy
- NUVB Strong Buy
- Analyst Count
- HCKT 3
- NUVB 6
- Target Price
- HCKT $32.67
- NUVB $8.33
- AVG Volume (30 Days)
- HCKT 122.0K
- NUVB 3.1M
- Earning Date
- HCKT 05-06-2025
- NUVB 03-06-2025
- Dividend Yield
- HCKT 1.65%
- NUVB N/A
- EPS Growth
- HCKT N/A
- NUVB N/A
- EPS
- HCKT 1.05
- NUVB N/A
- Revenue
- HCKT $307,028,000.00
- NUVB $7,873,000.00
- Revenue This Year
- HCKT $7.67
- NUVB $47.99
- Revenue Next Year
- HCKT $4.54
- NUVB $551.81
- P/E Ratio
- HCKT $27.86
- NUVB N/A
- Revenue Growth
- HCKT 5.41
- NUVB N/A
- 52 Week Low
- HCKT $20.23
- NUVB $1.71
- 52 Week High
- HCKT $34.02
- NUVB $3.97
- Technical
- Relative Strength Index (RSI)
- HCKT 47.49
- NUVB 36.74
- Support Level
- HCKT $28.23
- NUVB $1.85
- Resistance Level
- HCKT $29.51
- NUVB $2.04
- Average True Range (ATR)
- HCKT 0.63
- NUVB 0.16
- MACD
- HCKT 0.14
- NUVB -0.01
- Stochastic Oscillator
- HCKT 80.23
- NUVB 1.81
About HCKT Hackett Group Inc (The).
The Hackett Group Inc is an IP platform-based Generative Artificial Intelligence (Gen AI) strategic consulting and executive advisory digital transformation firm. The Hackett Group provides dedicated expertise in Gen AI-enabled enterprise transformation services across the front, mid and back office areas, including its highly recognized Oracle, SAP, OneStream and Coupa implementation offerings. It operates in three segments Oracle Solutions, SAP Solutions, and Global S&BT. It generates the majority of its revenue from the Global S&BT segment in the United States.
About NUVB Nuvation Bio Inc.
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. The company's clinical-stage product candidate is NUV-868, a BD2-selective oral small molecule BET inhibitor. NUV-868 inhibits the protein BRD4, a key member of the BET family that epigenetically regulates a number of important proteins that control tumor growth and differentiation, including oncogenes such as c-myc. Notably, BET proteins have critical biological functions and are found to be altered in many human cancers. It is also developing its proprietary, small molecule Drug-Drug Conjugate (DDC) platform, a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies with parallels to Antibody-Drug Conjugates (ADCs).